Madrigal Pharmaceuticals, Inc.

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be? Scrip has int

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted str